Corbus Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery

Press Release Webcast

Press Releases

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

September 20, 2018

Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union

September 18, 2018

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting

September 14, 2018

Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference

August 23, 2018

Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update

August 8, 2018

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis

July 25, 2018

Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis

July 20, 2018

Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference

June 21, 2018

Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference

June 14, 2018

Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018

June 13, 2018

1
2
3
4
5
6
7
8
9
10
...13
Next »

Latest News

Sep 20, 2018 • 7:00 AM EDT

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

About

Corbus Pharmaceuticals is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates.

Learn More

Product Pipeline

Our pipeline is built on robust underlying science based on the endocannabinoid system as a master regulator of inflammation and fibrosis in the body.

Learn More